Date: 2012-11-08
Type of information:
Compound: protease inhibitors
Company: Grunenthal (Germany) Amura Therapeutics (UK)
Therapeutic area: Inflammatory diseases - CNS diseases
Type agreement: R&D
Action mechanism:
Disease: pain
inflammation
Details: The Grünenthal Group and Amura Therapeutics have entered into a collaboration agreement. The focus of this collaboration is the development of protease inhibitors which play a key role in pain and inflammation, key focus areas in Grünenthal’s research-focused Strategic Business Unit Grünenthal Innovation.
Under the terms of the agreement Grünenthal and Amura will combine their respective expertise to collaborate on the development of cathepsin inhibitors to treat pain and inflammation. Starting from advanced lead compounds generated from Amura, Grünenthal will add its key expertise to the continued development of these small molecule drugs and assume responsibility for further research and development.
Financial terms: Grünenthal takes exclusive rights for worldwide clinical development, manufacturing and commercialisation of potential new pharmaceutical products arising from the collaboration. Grünenthal has made an undisclosed upfront payment, will make further milestone payments and is funding the costs under the running agreement.
Latest news:
